Form 4: Pacira BioSciences Director Alethia Young Acquires Shares and Stock Options

Director Alethia Young reports acquisition of Pacira BioSciences common stock and stock options.

Summary

• On June 12, 2024, Alethia Young, a director of Pacira BioSciences, acquired 5,230 shares of common stock.
• These shares were acquired at a price of $0.
• Following the transaction, Young directly owns 5,230 shares of Pacira BioSciences common stock.
• Young also acquired stock options for 12,179 shares of common stock at an exercise price of $28.68, exercisable from June 12, 2025, to June 12, 2034.
• These options were also acquired at a price of $0.
• The restricted stock units vest on June 12, 2025, contingent upon continued service with Pacira BioSciences.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects standard insider trading activity. The acquisition of shares and options by a director could be seen as a positive signal, but without further context, it's difficult to gauge the overall impact.

Positives

• A director's acquisition of shares and options may signal confidence in the company's future prospects.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting of restricted stock units is contingent upon continued service with the issuer.

Industry Context

This filing reflects insider transactions, which are routinely monitored by investors to gauge management's sentiment and confidence in the company's performance and future prospects within the biotechnology industry.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if interpreted as a sign of confidence from a company director.

Key Dates